Lepu Biopharma (HKG:2157) said China's National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for its cancer drug candidate MRG003, according to a Friday filing on the Hong Kong bourse.
The drug treats recurrent or metastatic nasopharyngeal cancer (R/M NPC). The Food and Drug Administration (FDA) previously granted it Fast Track Designation (FTD).
The company's stocks were up by 8% in recent trading.
Price (HKD): $3.42, Change: $+0.26, Percent Change: +8.23%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments